Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fulcrum Therapeutics (FULC) Research & Development (2018 - 2026)

Fulcrum Therapeutics (FULC) has 9 years of Research & Development data on record, last reported at $14.1 million in Q1 2026.

  • On a quarterly basis, Research & Development rose 5.07% to $14.1 million in Q1 2026 year-over-year; TTM through Mar 2026 was $56.8 million, a 0.41% change, with the full-year FY2025 number at $56.1 million, down 11.49% from a year prior.
  • Research & Development reached $14.1 million in Q1 2026 per FULC's latest filing, down from $15.4 million in the prior quarter.
  • Over the last five years, Research & Development for FULC hit a ceiling of $25.0 million in Q2 2022 and a floor of $11.7 million in Q4 2024.
  • A 5-year average of $16.6 million and a median of $16.7 million in 2023 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: surged 43.97% in 2022, then tumbled 38.35% in 2024.
  • Tracing FULC's Research & Development over 5 years: stood at $18.6 million in 2022, then grew by 2.33% to $19.0 million in 2023, then crashed by 38.35% to $11.7 million in 2024, then skyrocketed by 31.61% to $15.4 million in 2025, then dropped by 8.64% to $14.1 million in 2026.
  • Business Quant data shows Research & Development for FULC at $14.1 million in Q1 2026, $15.4 million in Q4 2025, and $14.3 million in Q3 2025.